🇺🇸 FDA
Pipeline program

CBP-201

CBP-201-CN003

Phase 3 small_molecule active

Quick answer

CBP-201 for Atopic Dermatitis is a Phase 3 program (small_molecule) at Connect Biopharma Holdings Ltd with 2 ClinicalTrials.gov record(s).

Program details

Company
Connect Biopharma Holdings Ltd
Indication
Atopic Dermatitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials